RSV is the leading cause of hospitalization among children less than a year old, according to scientists.

Eli Lilly is racing to market donanemab for Alzheimer’s after Eisai and Biogen’s drug for the disease, Leqembi, won FDA approval this month.

But settling soon seems unlikely, Diller said, since “there’s no trust between the parties.”